| Astellas Pharma Global Development Inc. |
1517-CL-1003 |
A phase 3, open-label, uncontrolled study to evaluate the activity, safety, pharmacokinetics and pharmacodynamics of roxadustat for the treatment of anemia in pediatric participants with chronic kidney disease. |
İLMAY BİLGE (Prof.Dr.) |
Phase 3 |
Nephrology |
Chronic Kidney Disease |